We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.055 | -2.52% | 2.125 | 2.05 | 2.20 | 2.25 | 2.10 | 2.20 | 2,365,381 | 16:35:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.89 | 7.17M |
Date | Subject | Author | Discuss |
---|---|---|---|
25/3/2024 12:35 | The Incanthera direct holding must be worth gbp1.5m after todays rise plus 7.3m warrants which can be exercised anytime, so warrants presumably worth another gbp1.25m approx. This is what i call hidden value on the balance sheet. | rimau1 | |
25/3/2024 12:30 | Good to see the rise for the LTHs here and the recent punters. It is somewhat ironic that the rise is due to the success of another company…but beggars can’t be choosers. | nobbygnome | |
25/3/2024 12:23 | Nice and quiet on here at moment, steady as she blows,when will all the Muppets arrive slagging it off lol GLA | courty2 | |
25/3/2024 09:49 | Money moving to APH [LSE] , excellent profitable healthcare company | blackhorse23 | |
22/3/2024 15:18 | Still life in the old dog yet. | tewkesbury | |
15/3/2024 14:00 | stockriser - the announcement of no further dilution for now was, on the face of it, undoubtedly good news. It calmed market nerves & marked a turning point in share price direction. That said, past pronouncements - notably from Tim M - have often proved unreliable. Also, any sale of IMM’s Incanthera holding would, in effect, just be dilution by the back door. Hopefully a commercial deal will come along before then to make this option unnecessary. | lord loads of lolly | |
15/3/2024 11:35 | ...and it's worth reminding ourselves. This isn't a one-trick-pony. Many potential game changers in the pipeline. Multiple shots on goal. | the imperialist | |
15/3/2024 11:28 | TI - Totally agree with you, Mcap is ridiculous for this Co., with so much potential and also as you say no further dilution. | stockriser | |
15/3/2024 11:25 | The Co. confirmed no further dilution. For me that calls the bottom. The upside here is huge. | the imperialist | |
15/3/2024 11:24 | Many think this may drop back a bit so they can get in lower - Hmmm, not so sure myself. GLA SR | stockriser | |
15/3/2024 09:53 | Me too, but trying to keep this under the RADAR. | the imperialist | |
15/3/2024 09:30 | Good morning More interest in these today with a decent share price gain. No new published news though I hold few. | maytrees | |
11/3/2024 08:08 | Paul Scott effect!!! He's took a punt pos fame | bloomberg2 | |
07/3/2024 15:48 | Shush!Shush! | bingham | |
06/3/2024 15:26 | Tks SK - Great interview | stockriser | |
06/3/2024 12:20 | nobbygnome - You say IMM looks cheap, is priced to fail and that its holding & warrants in Incanthera could prove a significant asset. So despite your reservations about any imminent deals to provide upfront cash, do you regard IMM as over or under valued at its current level (post-today's uptick)? Notwithstanding McCarthy's pre-disposition to - ahem - exaggerate, I view today's RNS as a major positive. Assuming he doesn't totally go back on his word in a few weeks' time (admittedly a big assumption), surely the major fear that IMM was about to go bust has been dispelled. For now at least. To me, this is now a share to hold & sell closer to (but importantly before!) any trial readout. Your thoughts? | lord loads of lolly | |
06/3/2024 09:54 | End of dilution! Nothing to see here :-) | the imperialist | |
06/3/2024 09:49 | RNS seems to be a balanced view on where the company is and where it could go; a more measured view to the market based on the look forward activity and fiscal position. Regular updates on progress should underpin the view of the RNS and provide confidence on the trajectory outlined in the RNS. | colsmith | |
06/3/2024 09:08 | Avion is investing $25 million in the P3 that is starting this year. That investment alone is worth multiples of the current market cap. | sicilian_kan | |
06/3/2024 09:01 | And I agree Icanthera could be a significant asset…. | nobbygnome | |
06/3/2024 09:01 | The last upfront was a big fact ZERO so it would be difficult for it to be lower…. | nobbygnome | |
06/3/2024 09:00 | Nobby, start another Guild lol Jeez… is that McCarthy still drawing his pension, this one is going nowhere but down, with jittery dead cat bounces | ny boy | |
06/3/2024 09:00 | P.S. They already have two deals, on US rights in Lupuzor with P3 fully funded, and 10% of Incancthera that has a deal with the worlds largest international health and beauty retailer. This is just not factored into the share price. | sicilian_kan | |
06/3/2024 08:59 | Because they will structure the deal differently. On Lupuzor US rights, they focused on royalty rates getting double digit tiered up to 17%. I suspect they will reduce that a little on CIPD to get a bigger up front payment. | sicilian_kan | |
06/3/2024 08:55 | You make some good points S_K but you are definitely over egging the pudding. Pre clinical programs are of little interest to Pharma so don’t expect any upfront if they get a deal there. And why do you think CIDP will get a significant upfront when SLE got zero upfront? I don’t dispute it looks cheap if they actually achieve some sort of deal but…. | nobbygnome |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions